Journal
ANTIBIOTICS-BASEL
Volume 6, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/antibiotics6010003
Keywords
antibiotic resistant pulmonary tuberculosis; thioridazine; in vitro activity; ex vivo activity; in vivo activity (murine model and human trails); the non-killing macrophage; enhancement of intracellular killing of Mtb by thioridazine; mechanism of actions of thioridazine
Categories
Funding
- FCT Fundacao para a Ciencia e a Tecnologia (FCT) [UID/Multi/04413/2013]
- FCT
- Gulbenkian Foundation
Ask authors/readers for more resources
This review presents the evidence that supports the use of thioridazine (TZ) for the therapy of a pulmonary tuberculosis infection regardless of its antibiotic resistance status. The evidence consists of in vitro and ex vivo assays that demonstrate the activity of TZ against all encountered Mycobacterium tuberculosis (Mtb) regardless of its antibiotic resistance phenotype, as well as in vivo as a therapy for mice infected with multi-drug resistant strains of Mtb, or for human subjects infected with extensively drug resistant (XDR) Mtb. The mechanisms of action by which TZ brings about successful therapeutic outcomes are presented in detail.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
